title: E6 viral protein ratio correlates with outcomes in human papillomavirus related oropharyngeal cancer.
abstract: The study aimed to identify prognostic markers to improve the management of patients with HPV positive OSCC Methods: We determined the ratio of HPV E6*I and E6*II splice variants by quantitative RT-PCR in 177 HPV positive OSCC and correlated the findings with other clinicopathological data Results: There was no significant difference in locoregional recurrence (HR 1.72 p = 0.24) and death (HR 1.65, p = 0.13) among patients whose tumors had an E6*I/*II ratio ≥1 compared with an E6*I/*II ratio of <1. Univariate analysis showed that patients with E6*I/*II ≥1 OSCC were more likely to have an event. In the multivariable analysis, there was a trend for more events in patients with E6*I/*II ratio ≥1 (HR 1.70, 95% CI 0.95-3.03, p = 0.07) CONCLUSION: Our data suggest that the use of HPV 16 spliced transcripts may help to predict for poorer outcomes in patients with HPV positive OSCC.
authors.affiliation: a Central Clinical School, Sydney Medical School, The University of Sydney , NSW , Australia.|b Department of Radiation Oncology , Lifehouse , NSW , Australia.
authors.forename: Angela
authors.initials: A
authors.lastname: Hong
authors.affiliation: c Department of Infectious Diseases and Immunology , Sydney Medical School, The University of Sydney , NSW , Australia.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Zhang
authors.affiliation: c Department of Infectious Diseases and Immunology , Sydney Medical School, The University of Sydney , NSW , Australia.
authors.forename: Deanna
authors.initials: D
authors.lastname: Jones
authors.affiliation: a Central Clinical School, Sydney Medical School, The University of Sydney , NSW , Australia.|b Department of Radiation Oncology , Lifehouse , NSW , Australia.
authors.forename: Mei
authors.initials: M
authors.lastname: Zhang
authors.affiliation: d Department of Anatomical Pathology , Royal Prince Alfred Hospital , Camperdown , NSW , Australia.
authors.forename: C Soon
authors.initials: CS
authors.lastname: Lee
authors.affiliation: a Central Clinical School, Sydney Medical School, The University of Sydney , NSW , Australia.
authors.forename: J Guy
authors.initials: JG
authors.lastname: Lyons
authors.affiliation: e NHMRC Clinical Trials Center, The University of Sydney , NSW , Australia.
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Veillard
authors.affiliation: c Department of Infectious Diseases and Immunology , Sydney Medical School, The University of Sydney , NSW , Australia.
authors.forename: Barbara
authors.initials: B
authors.lastname: Rose
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000473:pathology / Q000821:virology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000235:genetics*; D009959:Oropharyngeal Neoplasms / Q000235:genetics* / Q000473:pathology / Q000821:virology; D027383:Papillomaviridae / Q000235:genetics / Q000472:pathogenicity; D011379:Prognosis; D022821:RNA Splice Sites / Q000235:genetics; D012097:Repressor Proteins / Q000235:genetics*; D012307:Risk Factors
chemical_list: C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D022821:RNA Splice Sites; D012097:Repressor Proteins
keywords: E6; head and neck cancer; human papillomavirus; oropharyngeal cancer; p16